Majid Zeidi Research Associate (University of California San Francisco)
Dermatopathologist, Dermpath diagnostics, Cincinnati, OH · United States
Editorial leadership for Journal of Dermatologic Research And Therapy ISSN 2471-2175
Research interests
- Medicine
- Pathology
- Immunology
- Dermatopathology
- Autoimmune Skin Diseases
- Cutaneous Lupus Erythematosus
Biography
Dr. Majid Zeidi is a board-certified pathologist who completed his fellowship in dermatopathology at the University of California, San Francisco (UCSF). He currently serves as a dermatopathologist at Dermpath Diagnostics in Cincinnati, Ohio, United States. His research interests focus on the cellular and molecular mechanisms that control immune-mediated inflammation in skin diseases such as cutaneous lupus erythematosus and dermatomyositis. Dr. Zeidi is a member of the College of American Pathologists and has authored or co-authored numerous articles, including his most-cited publication on the safety and efficacy of lenabasum in patients with dermatomyositis with refractory skin disease, published in 2022.
Selected publications
- Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial 2022 cited 48×
- Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness 2021 cited 28×
- Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM 2022 cited 22×
- Increased MxA protein expression and dendritic cells in spongiotic dermatitis differentiates dermatomyositis from eczema in a single‐center case‐control study 2020 cited 11×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JDRT for your work?
This journal is guided by Majid Zeidi (Dermatopathologist, Dermpath diagnostics, Cincinnati, OH) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.